<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37666997</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1759-4804</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Nature reviews. Rheumatology</Title><ISOAbbreviation>Nat Rev Rheumatol</ISOAbbreviation></Journal><ArticleTitle>SGLT2 inhibitors protect podocytes in lupus nephritis.</ArticleTitle><Pagination><StartPage>605</StartPage><MedlinePgn>605</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41584-023-01024-1</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Onuora</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Nature Reviews Rheumatology, . nrrheum@nature.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Rev Rheumatol</MedlineTA><NlmUniqueID>101500080</NlmUniqueID><ISSNLinking>1759-4790</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077203">Sodium-Glucose Transporter 2 Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077203" MajorTopicYN="Y">Sodium-Glucose Transporter 2 Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050199" MajorTopicYN="Y">Podocytes</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>5</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>4</Day><Hour>23</Hour><Minute>31</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37666997</ArticleId><ArticleId IdType="doi">10.1038/s41584-023-01024-1</ArticleId><ArticleId IdType="pii">10.1038/s41584-023-01024-1</ArticleId></ArticleIdList><ReferenceList><ReferenceList><Title>Original article</Title><Reference><Citation>Zhao, X.-Y. et al. SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy. Ann. Rheum. Dis. https://doi.org/10.1136/ard-2023-224242 (2023)</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard-2023-224242</ArticleId><ArticleId IdType="pubmed">37487609</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>